Hikal Limited has informed the Exchange that Board of Directors at its meeting held on May 27, 2026, recommended Final Dividend of Rs. 0.40 per equity share.
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.5 pts less than Nifty Microcap 250 and 11.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Limited reported a net loss of Rs. 487 million for FY 2025-26, a sharp decline from profit of Rs. 909 million in the previous year. Revenue from operations fell to Rs. 17,126 million from Rs. 18,598 million, driven by USFDA warning letter impact on Pharma segment sales. The company recorded exceptional items totaling Rs. 851 million, including Rs. 471 million impairment charge for plant repurposing and Rs. 380 million due to new labour code implementation. The Board recommended final dividend of Rs. 0.40 per share (20%), bringing total dividend for the year to Rs. 0.60 per share (30%), significantly lower than previous year's Rs. 1.40 per share (70%). Auditors issued an unmodified opinion but drew attention to an environmental compliance matter pending before the Supreme Court. Operating cash flow remained healthy at Rs. 3,021 million.
The company swung to a loss due to exceptional items and revenue decline, raising concerns about profitability. The sharply reduced dividend (down 57% from last year) signals financial stress. However, positive operating cash flow and unmodified audit opinion provide some comfort about the company's ability to continue as a going concern.